Document Type : Original Article(s)


1 Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

2 Professor, Cellular and Molecular Research Center AND Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

3 Associate Professor, Department of Cardiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

4 Assistant Professor, Department of Immunology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

5 Professor, Department of Physiology, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

6 Professor, Zanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran


BACKGROUND: Cardiac syndrome X (CSX) has been associated with endothelial dysfunction and inflammation. We conducted a case-control study to evaluate the association between platelet‎ and endothelial-derived microparticles (PMPs and EMPs), as specific quantitative plasma markers of endothelial dysfunction, and the presence of CSX.METHODS: The present study was conducted on 40 CSX patients and 19 healthy individuals. C-reactive protein (CRP), and hematological and biochemical parameters were evaluated. The MP concentration in platelet-poor plasma (PPP) was quantitatively determined through flow cytometry using specific anti-human CD31, CD41a, CD62E, and CD144antibodies.RESULTS: The mean platelet volume (MPV) and positive CRP rate (≥ 3.8 mg/l) were higher in patients compared to controls (P = 0.020 and P = 0.010, respectively). The CD62E+, CD144+, and CD31+41− EMPs, as well as CD41+ and CD31+CD41+ PMPs showed significant increase in CSX patients compared to controls (P < 0.050). There were direct correlations between the mean percentage of detected EMPs and PMPs as well as between their expression intensity; however, a reverse correlation was seen between the percentage of MPs and CD144and CD41. Moreover, the MP level was reversely associated with prothrombin time (PT) and partial thromboplastin time (PTT) values. Only CD31+CD41+ PMP was correlated with CRP.CONCLUSION: It seems that EMPs and PMPs increase in CSX, which may contribute to various processes involved in the development of this syndrome.


  1. Agrawal S, Mehta PK, Bairey Merz CN. Cardiac syndrome X: Update. Heart Fail Clin 2016; 12(1): 141-56.
  2. Recio-Mayoral A, Rimoldi OE, Camici PG, Kaski JC. Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging 2013; 6(6): 660-7.
  3. Arroyo-Espliguero R, Kaski JC. Microvascular dysfunction in cardiac syndrome X: the role of inflammation. CMAJ 2006; 174(13): 1833.
  4. Wu EB. Microvascular dysfunction in patients with cardiac syndrome X. Heart 2009; 95(7): 521.
  5. Huang PH, Chen YH, Chen YL, Wu TC, Chen JW, Lin SJ. Vascular endothelial function and circulating endothelial progenitor cells in patients with cardiac syndrome X. Heart 2007; 93(9): 1064-70.
  6. Shmilovich H, Deutsch V, Roth A, Miller H, Keren G, George J. Circulating endothelial progenitor cells in patients with cardiac syndrome X. Heart 2007; 93(9): 1071-6.
  7. Rasmi Y, Rouhrazi H, Khayati-Shal E, Shirpoor A, Saboory E. Association of endothelial dysfunction and cytotoxin-associated gene A-positive Helicobacter pylori in patients with cardiac syndrome X. Biomed J 2016; 39(5): 339-45.
  8. Efe SC, Demirci K, Ozturk S, Gurbuz AS, Poci N, Kilicgedik A, et al. Serum endocan levels in patients with cardiac syndrome X. Herz 2018; 43(4): 359-63.
  9. Tousoulis D, Davies GJ, Asimakopoulos G, Homaei H, Zouridakis E, Ahmed N, et al. Vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol 2001; 24(4): 301-4.
  10. Helal O, Defoort C, Robert S, Marin C, Lesavre N, Lopez-Miranda J, et al. Increased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutr Metab Cardiovasc Dis 2011; 21(9): 665-71.
  11. Diehl P, Aleker M, Helbing T, Sossong V, Germann M, Sorichter S, et al. Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension. J Thromb Thrombolysis 2011; 31(2): 173-9.
  12. Sansone R, Baaken M, Horn P, Schuler D, Westenfeld R, Amabile N, et al. Release of endothelial microparticles in patients with arterial hypertension, hypertensive emergencies and catheter-related injury. Atherosclerosis 2018; 273: 67-74.
  13. Berezin AE, Kremzer AA, Martovitskaya YV, Berezina TA, Gromenko EA. Pattern of endothelial progenitor cells and apoptotic endothelial
  14. cell-derived microparticles in chronic heart failure patients with preserved and reduced left ventricular ejection fraction. EBioMedicine 2016; 4: 86-94.
  15. VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in cardiovascular diseases. Cardiovasc Res 2003; 59(2): 277-87.
  16. Franca CN, Pinheiro LF, Izar MC, Brunialti MK, Salomao R, Bianco HT, et al. Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J 2012; 76(3): 729-36.
  17. Berezin A, Zulli A, Kerrigan S, Petrovic D, Kruzliak P. Predictive role of circulating endothelial-derived microparticles in cardiovascular diseases. Clin Biochem 2015; 48(9): 562-8.
  18. Pirro M, Schillaci G, Bagaglia F, Menecali C, Paltriccia R, Mannarino MR, et al. Microparticles derived from endothelial progenitor cells in patients at different cardiovascular risk. Atherosclerosis 2008; 197(2): 757-67.
  19. Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009; 54(7): 601-8.
  20. Horn P, Baars T, Kahlert P, Heiss C, Westenfeld R, Kelm M, et al. Release of intracoronary microparticles during stent implantation into stable atherosclerotic lesions under protection with an aspiration device. PLoS One 2015; 10(4): e0124904.
  21. Ayers L, Kohler M, Harrison P, Sargent I, Dragovic R, Schaap M, et al. Measurement of circulating cell-derived microparticles by flow cytometry: Sources of variability within the assay. Thromb Res 2011; 127(4): 370-7.
  22. Dey-Hazra E, Hertel B, Kirsch T, Woywodt A, Lovric S, Haller H, et al. Detection of circulating microparticles by flow cytometry: Influence of centrifugation, filtration of buffer, and freezing. Vasc Health Risk Manag 2010; 6: 1125-33.
  23. Amabile N, Guerin C, Caussin C, Blanc-Brude O, Boulanger CM. Increased levels of circulating endothelial microparticles and erythrocytes degradation products in microvascular angina. Eur Heart J 2012; 33: 26.
  24. Dursun I, Poyrazoglu HM, Gunduz Z, Ulger H, Yykylmaz A, Dusunsel R, et al. The relationship between circulating endothelial microparticles and arterial stiffness and atherosclerosis in children with chronic kidney disease. Nephrol Dial Transplant 2009; 24(8): 2511-8.
  25. Koga H, Sugiyama S, Kugiyama K, Watanabe K, Fukushima H, Tanaka T, et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2005; 45(10): 1622-30.
  26. Horn P, Amabile N, Angeli FS, Sansone R, Stegemann B, Kelm M, et al. Dietary flavanol intervention lowers the levels of endothelial microparticles in coronary artery disease patients. Br J Nutr 2014; 111(7): 1245-52.
  27. Wekesa AL, Cross KS, O'Donovan O, Dowdall JF, O'Brien O, Doyle M, et al. Predicting carotid artery disease and plaque instability from cell-derived microparticles. Eur J Vasc Endovasc Surg 2014; 48(5): 489-95.
  28. Lee ST, Chu K, Jung KH, Kim JM, Moon HJ, Bahn JJ, et al. Circulating CD62E+ microparticles and cardiovascular outcomes. PLoS One 2012; 7(4): e35713.
  29. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003; 109(4): 175-80.
  30. Gordon C, Gudi K, Krause A, Sackrowitz R, Harvey BG, Strulovici-Barel Y, et al. Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. Am J Respir Crit Care Med 2011; 184(2): 224-32.
  31. Schiro A, Wilkinson FL, Weston R, Smyth JV, Serracino-Inglott F, Alexander MY. Endothelial microparticles as conveyors of information in atherosclerotic disease. Atherosclerosis 2014; 234(2): 295-302.
  32. Leroyer AS, Anfosso F, Lacroix R, Sabatier F, Simoncini S, Njock SM, et al. Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. Thromb Haemost 2010; 104(3): 456-63.
  33. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: A potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006; 48(2): 180-6.
  34. Dollard J, Kearney P, Clarke G, Moloney G, Cryan JF, Dinan TG. A prospective study of C-reactive protein as a state marker in Cardiac Syndrome X. Brain Behav Immun 2015; 43: 27-32.
  35. Laresche C, Pelletier F, Garnache-Ottou F, Lihoreau T, Biichle S, Mourey G, et al. Increased levels of circulating microparticles are associated with increased procoagulant activity in patients with cutaneous malignant melanoma. J Invest Dermatol 2014; 134(1): 176-82.
  36. Demirkol S, Balta S, Unlu M, Yuksel UC, Celik T, Arslan Z, et al. Evaluation of the mean platelet volume in patients with cardiac syndrome X. Clinics (Sao Paulo) 2012; 67(9): 1019-22.
  37. Salem M, Kamal S, El Sherbiny W., Abdel Aal AA. Flow cytometric assessment of endothelial and platelet microparticles in preeclampsia and their relation to disease severity and Doppler parameters. Hematology 2015; 20(3): 154-9.
  38. Rasmi Y, Zeynalzadeh J, Shirpoor A, Seyedmohammadzad M, Hajhosseini R. Lipid profile in cardiac syndrome x: Association with helicobacter pylori. J Clin Diagn Res 2016; 10(7): BC07-BC09.
  39. Liu QM, Zhou SH, Qi SS, Zhao SP, Minghuib L. Significance of the lipid profile and endothelium-dependent vasodilatation in the pathogenesis of microvascular angina. Cardiol J 2008; 15(4): 324-8.
  40. Mikirova N, Casciari J, Hunninghake R, Riordan N. Increased level of circulating endothelial micro particles and cardiovascular risk factors. J Clinic Experiment Cardiol 2011; 2(131): 2.
  41. Wannamethee SG, Shaper AG, Perry IJ. Serum creatinine concentration and risk of cardiovascular disease: A possible marker for increased risk of stroke. Stroke 1997; 28(3): 557-63.